BIS Industrietechnik Salzburg, a subsidiary of the Bilfinger Berger Industrial Services Group, has been awarded a contract by US biotech company Genzyme for the mechanical installation of a production facility to produce the active agent in a treatment for Pompe Disease.
The heart of the plant, which is to be built in Geel in Belgium, is formed by two production lines each comprising a 4,000 litre bioreactor for producing the therapeutic protein Myozyme. The plant is to be completed by the end of September 2012. The general architect for the plant is the PM Group, Ireland. The contract has a total volume of EUR 30 million. ...